Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Evaluation of the hydroxylamine tempol-H as an in vivo radioprotector
Stephen M. Hahn
, Murali C. Krishna
, Anne Marie Deluca
, Deborah Coffin
, James B. Mitchell
Research output
:
Contribution to journal
›
Article
›
peer-review
93
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Evaluation of the hydroxylamine tempol-H as an in vivo radioprotector'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Hydroxylamine
100%
Tempol
100%
Radioprotector
100%
C3H Mice
17%
Whole Blood
17%
Nitroxide
17%
Blood Pressure
8%
Radioprotection
8%
Maximum Tolerated Dose
4%
Lethality
4%
Intravenous Injection
4%
Systemic Administration
4%
Peak Concentration
4%
Intraperitoneal Injection
4%
Reactive Oxygen Species
4%
Substantial Reduction
4%
After Injection
4%
Blood Levels
4%
Intraperitoneal Route
4%
Active Form
4%
Dose Adjustment
4%
Pharmacology
4%
Whole-body Exposure
4%
Equilibration
4%
Seizure Activity
4%
Electron Paramagnetic Resonance Spectroscopy
4%
Arterial Blood Pressure
4%
Hemodynamic Assessment
4%
Cell Permeable
4%
Blood Pulse
4%
Modification Factor
4%
Milwaukee
4%
Stable Free Radical
4%
Pressure Experiment
4%
Rapid Oxidation
4%
Increasing Dose
4%
Pharmacology, Toxicology and Pharmaceutical Science
Tempol
100%
Hydroxylamine
100%
C3H Mouse
17%
Nitroxide
17%
Maximum Tolerated Dose
4%
Lethality
4%
Reactive Oxygen Metabolite
4%
Systemic Administration
4%
Free Radical
4%
Intraperitoneal Injection
4%
Hydrophile
4%
Neuroscience
In Vivo
100%
Tempol
100%
In Vitro
8%
Reactive Oxygen Species
4%
Spectroscopy
4%
Intraperitoneal Injection
4%
Free Radical
4%